356532-64-4

Basic information

• Product Name: N-(2-phenoxyethyl)cyclohexanamine
• Synonyms: N-(2-phenoxyethyl)cyclohexanamine
• CAS NO: 356532-64-4
• Molecular Formula: C₁₄H₂₁NO
• Molecular Weight: 219.326
• Mol File: 356532-64-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(2-phenoxyethyl)cyclohexanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-phenoxyethyl)cyclohexanamine(356532-64-4)
• EPA Substance Registry System: N-(2-phenoxyethyl)cyclohexanamine(356532-64-4)

Safety Data

• Hazardous Substances Data: 356532-64-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(2-phenoxyethyl)cyclohexanamine is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its role in drug development is crucial as it aids in the creation of new medications to treat a range of medical conditions.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, N-(2-phenoxyethyl)cyclohexanamine serves as a key intermediate in the synthesis of other organic compounds, contributing to the development of novel chemical entities with potential applications in various industries.

Upstream product

• 626-62-0 Cyclohexyl iodide 
• 1758-46-9 2-phenoxyethanamine 
• 108-95-2 phenol 
• 108-91-8 cyclohexylamine 
• 589-10-6 phenoxyethyl bromide 

Downstream Products

• 1224199-64-7 N-cyclohexyl-N-(2-phenoxyethyl)acetamide 

Relevant articles and documents

Copper-Catalyzed Alkylation of Aliphatic Amines Induced by Visible Light

Although the alkylation of an amine by an alkyl halide serves as a textbook example of a nucleophilic substitution reaction, the selective mono-alkylation of aliphatic amines by unactivated, hindered halides persists as a largely unsolved challenge in organic synthesis. We report herein that primary aliphatic amines can be cleanly mono-alkylated by unactivated secondary alkyl iodides in the presence of visible light and a copper catalyst. The method operates under mild conditions (-10 °C), displays good functional-group compatibility, and employs commercially available catalyst components. A trapping experiment with TEMPO is consistent with C-N bond formation via an alkyl radical in an out-of-cage process.

CYCLOHEXYLAMINE DERIVATIVE CONTAINING PHENYL GROUP, AND THERAPEUTIC AGENT FOR DISEASES ACCOMPANIED BY CENTRAL NERVOUS SYSTEM DISORDERS

Disclosed is a novel cyclohexylamine derivative containing a phenyl group, which is useful as a novel sigma receptor ligand. Also disclosed is a therapeutic agent for diseases accompanied by a central nervous system disorder, which comprises the compound as an active ingredient. The therapeutic agent comprises a compound represented by general formula [1] or a pharmacologically acceptable salt thereof as an active ingredient: wherein X and Y independently represent a hydrogen atom, a halogen atom, a trihalomethyl group, a dihalomethyl group, a monohalomethyl group, a methoxy group, a hydroxyl group, or an alkyl group having 1 to 3 carbon atoms; R1, R2, R3 and R4 independently represent a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 3 carbon atoms, or an alkyl group having 1 to 3 carbon atoms; R5 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, or an alkylene group which has 2 to 4 carbon atoms and can bind to a carbon atom other than carbon atoms that bind to a nitrogen atom on the cyclohexyl ring to form a ring; n represents an integer of to 5; and represents a sulfur atom, a carbon atom, or an oxygen atom.